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Cholangiocytes proliferationAdamant progression of chronic cholangiopathies towards cirrhosis and limited therapeutic options leave a liver
transplantation the only effective treatment. Insulin-like growth factor 1 (IGF1) effectively blocks ﬁbrosis in
acutemodels of liver damage inmice, and a phase I clinical trial suggested an improved liver function. IGF1 targets
the biliary epithelium, but its potential beneﬁt in chronic cholangiopathies has not been studied. To investigate the
possible therapeutic effect of increased IGF1 expression, we crossed Abcb4−/− mice (a model for chronic
cholangiopathy), with transgenic animals that overexpress IGF1. The effect on disease progression was studied
in the resulting IGF1-overexpressingAbcb4−/−mice, and compared to that of Abcb4−/− littermates. The speciﬁcity
of this effect was further studied in an acute model of ﬁbrosis. The overexpression of IGF1 in transgenic Abcb4−/−
mice resulted in stimulation of ﬁbrogenic processes — as shown by increased expression of Tgfß, and collagens 1,
3 and 4, and conﬁrmed by Sirius red staining and hydroxyprolinemeasurements. Excessive extracellular matrix de-
positionwas favored by raise in Timp1 and Timp2, while a reduction of tPA expression indicated lower tissue remod-
eling. These effects were accompanied by an increase in expression of inﬂammation markers like Tnfα, and higher
presence of inﬁltrating macrophages. Finally, increased number of Ck19-expressing cells indicated proliferation of
biliary epithelium. In contrast to liver ﬁbrosis associated with hepatocellular damage, IGF1 overexpression does
not inhibit liver ﬁbrogenesis in chronic cholangiopathy.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Primary sclerosing cholangitis and primary biliary cirrhosis are chron-
ic diseases of the bile duct characterized by progressive inﬂammation that
leads to the development of biliary ﬁbrosis. There is no effective therapy
to halt the disease progression and most patients progress to cirrhosis
and liver failure [1,2]. The lack of sufﬁcient donor organs and surgical
contraindications render development of therapeutic interventions that
stop progression of liver ﬁbrosis urgently needed.
Insulin-like growth factor 1 (IGF1) regulates the proliferation and
differentiation ofmany cell types [3]. The liver is responsible for the abun-
dant presence of IGF1 in the circulation [4] where it is present attached to
binding proteins (IGFBPs) that prolong its half-life and regulate itsub-family B member 4; ECM,
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rights reserved.biological activity [3,5]. Once released from IGFBPs, IGF1 can bind and ac-
tivate the receptor (IGF1R), andby activationofmitogen activatedprotein
(MAP) kinase and PI3 kinase induce genes involved in cell survival,
growth, and differentiation [6]. Liver ﬁbrosis reduces the IGF1 expression
in the liver [7,8]. Administration of recombinant IGF1 or enhancing IGF1
expression using a viral vector signiﬁcantly reduced liver ﬁbrosis in rats
with CCl4-induced liver cirrhosis [9,10]. In the follow-up phase I–II clinical
trials, IGF1 administration increased the serum albumin level, suggesting
an improved liver function in patients suffering from this devastating
disease [11].
The potential use of IGF1 in chronic cholangiopathies has not been
studied. Since the biliary epithelium expresses IGF1R [12], and IGF1
protects cholangiocytes against cholestatic injury in vitro [13],
overexpression of IGF1 could be beneﬁcial in these diseases. There-
fore the aim of this study was to investigate if a prolonged increase
of hepatic IGF1 expression in a model for chronic cholangiopathy,
the Abcb4−/− mouse, was beneﬁcial.
The Abcb4−/−mouse is a model for primary familial cholestasis type
3 [14]. ABCB4 is a ﬂippase essential for the excretion of phospholipids
into bile, needed to neutralize the harmful effects of bile acids. Bile
lacking phospholipids is toxic and causes hepatocyte and cholangiocyte
injury [15]. Since murine bile acids are less toxic, the damage in the
Abcb4−/− is smaller compared to that in PFIC type 3 patients, making
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ically, primary sclerosing cholangitis (PSC) [16].To study the long term
effect of IGF1 on chronic cholangiopathy we crossbred the Abcb4−/−
with the transgenic SMP8-IGF1mouse. This transgenic mouse expresses
the rat IGF1 behind an α-SMA promoter [17]. The increased α-SMA
expression in Abcb4−/− livers [15] should make this cross-bred model
well suited for the study of long-term effects of IGF1 on PSC.
2. Materials and methods
2.1. Animals
This study was approved by the Ethical Committee for Animal Re-
search of the University of Navarra with the number: 008/08.
2.2. Abcb4−/− IGF1 model
HomozygousAbcb4−/−mice (FVBbackground; [18])were cross-bred
with transgenic SMP8-IGF1 mice, with a germline integration of a
transgene composed of themurineα-Smapromoter linked to a full length
rat Igf1 cDNA [17]. The resulting heterozygotes for Abcb4 were back-
crossed with Abcb4−/− mice to obtain Abcb4−/−SMP8-Igf1+/−
transgenic mice (TG) and their nontransgenic (NT) littermates as
a control. After weaning, the mice WT (FVB; n=4), Abcb4−/− (n=7)
and Abcb4−/− SMP8-Igf1+/− (n=7) were fed a 0.03% cholate diet to
augmentﬁbrosis, andwere sacriﬁced after 3, 6 and 12 weeks (WT control
for 3 weeks).
2.3. Bile duct ligation (BDL) model
SMP8-IGF1 (n=5) andWT (FVB; n=5) mice were bile duct ligated.
After a 1 cm abdominal midline incision, the common bile duct was
isolated, double ligated close to the liver hilus (immediately below the
bifurcation) with a silk suture, and transected between ligatures. In
sham operated mice (SMP8-IGF1 and WT; n=5), the same operation
was performed, but neither ligatures nor bile duct section were carried
out. All themice used in the protocolwere 12 weeks old at the beginning
of the experiment. The mice were sacriﬁced a week after BDL.
2.4. Tissue collection and biochemical analyses
Upon sacriﬁcing, blood was collected, livers were snap-frozen in
liquid nitrogen and stored at −80 °C, or ﬁxed in 4% formaldehyde inFig. 1. Functional expression of IGF-1 in livers of Abcb4−/−mice. After weaning, WT, Abcb4−
IGF1 (n=7) – were fed a 0.03% cholate diet. (A–C) mRNA levels of transgenic Igf1, α-Sma a
diet for 3, 6 and 12 weeks. D) Average fractional liver weight of Abcb4−/− and Abcb4−/− IGPBS. Total liver collagen was determined by measuring hydroxyproline
content as described [19] Serum transaminases (ALT and AST), alkaline
phosphatase and bilirubin were determined in retro-orbital collected
blood, using standard clinical chemistry methods in a Cobas C311
autoanalyzer (Roche Diagnostics, Mannheim, Germany).
2.5. Reverse transcription, quantitative PCR and data analyses
The qPCR analysis was performed and the data analyzed as previously
described [20]. Shortly, total liver RNA was extracted from snap-frozen
livers using TRIzol reagent (Invitrogen, Breda, TheNetherlands) following
the manufacturer's instructions. 4 M LiCl was used to speciﬁcally precip-
itate RNA. All RNA isolates had A260/A280 ratio around 2, as assessed by
NanoDrop ND-1000 spectrophotometer. The RNA integrity was con-
ﬁrmed by denaturing agarose gel electrophoresis. The absence of DNA
contamination was established by including RT-controls in cDNA synthe-
sis reactions. Gene speciﬁc primers (for Igf1, Hgf, α-Sma, Tgfb, Col1, Col3,
Col4, Timp1, Timp2, tPa, Tnfα, Ki67 and Ck19) were designed using
Primer3Plus program and their sequences are available upon request.
qPCR was performed using a Light Cyler 480 (Roche) as described [21].
The expression level for each of the studied genes in liver was calculated
using the LinRegPCR software [22,23], thereby avoiding the assumptionof
equal ampliﬁcation efﬁciency between the reactions. Gene expression
was normalized by dividing the expression levels of tested genes by
those of a reference gene (36B4), and calculating the average of normal-
ized values per condition. 36B4 was used only after having validated it
against three reference genes in our previous studies [24]. In BDL model,
qPCR was performed as previously described [25]. To assess the signiﬁ-
cance of the data, ANOVA analysis and Student's t test were employed.
The error bars in theﬁgures represent the standarddeviation. Signiﬁcance
threshold was set to Pb0.05 (denoted by the asterisks in the ﬁgures and
tables).
2.6. Histology and immunohistochemistry
Formaldehyde-ﬁxed liver sections were stained with Sirius red
(morphometrical connective tissue assessment), or immunohisto-
chemically, as described [26]. Liver collagen content was quantiﬁed
by Sirius red staining, using an Axioplan 2 Imaging microscope (Zeiss,
Jena, Germany); random acquisition of images was performed with
Metamorph software (Molecular Devices, Sunnyvale, CA, USA), and
scoring of areas was carried out with Matlab software and the imaging
processing libraries of DIPlib (MathWorks, Natick, MA, USA). Ck19/− and Abcb4−/− IGF1 mice –WT (n=4; for 3 weeks), Abcb4−/− (n=7) and Abcb4−/−
nd Hgf in livers of WT, Abcb4−/− and Abcb4−/− IGF1 mice fed a cholate supplemented
F1 mice, after 3, 6 and 12 weeks of cholate diet. Asterisks denote signiﬁcance (Pb0.05).
Table 1
The inﬂuence of IGF1 overexpression on liver function shown by clinical parameters in plasma.
ALT
(U/L)
AST
(U/L)
ALP
(U/L)
tBil
(mg/dl)
TP
(g/dl)
Chol
(mg/dl)
TG
(mg/dl)
WT
3 weeks 76.1±16.9 126.9±29.5 188.2±36.6 0.08±0.01 5.2±0.2 183.5±9.9 83.50±17.4
Abcb4−/−
3 weeks 355.4±125.8 502.5±186.9 1992.6±1257.6 0.2±0.2 5.2±0.3 107.2±25.9 137.3±24.7
6 weeks 185.3±95.4 238.7±74.8 448.8±319.5 0.2±0.1 5.3±0.8 103.6±28.7 144.9±12.9
12 weeks 356.6±220.3 591.1±460.4 285±136.4 0.3±0.3 5.9±0.5 80.1±16.6 89.14±34.2
Abcb4−/− IGF1
3 weeks 320.7±86.2 502.2±231.2 1020.5±657.4 0.2±0.1 5.9±0.5 112.9±15.9 116.6±29.1
6 weeks 238.5±127.7 314.6±152.9 533.4±323.2 0.2±0.1 5.4±1.4 101.5±29.8 132.1±56.7
12 weeks 388.8±191.2 600.9±322.7 1712.9±1095.5
*0.01
1.9±1.6
*0.0005
5.0±1.2 103.3±24.6 128.3±42.9
The table shows mean values and standard deviation of serum parameters measured in plasma of WT (n=4), Abcb4−/− (n=7) and Abcb4−/− IGF1 (n=7) mice. The differences
between Abcb4−/− and Abcb4−/− IGF1 mice were tested by Student's t-test, with asterisks denoting signiﬁcant difference (with the corresponding P-values shown next to the
tags). The values for WT are shown as a reference. ALT (alanine transaminase), AST (aspartate transaminase), ALP (alkaline phosphatase), tBil (total bilirubin), TP (total protein),
Chol (cholesterol), Tg (triglycerides).
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Glostrup, Denmark) as a secondary antibody. F4/80 (AbD Serotec,
Dusseldorf, Germany) was visualized using rabbit anti Rat-Ig (DAKO,
Glostrup, Denmark) as a secondary antibody.
Double staining for Ck19 and Ki67was performed on frozen sections,
ﬁxed for 5 min in ice cold acetone and air dried for 30 min. Slides were
rinsed in PBS, blocked for 30 min in TengT and incubated o/n at 4 °C
with the primary anti-Ki67 Ab (Abcam, Cambridge, UK; 1:500).Washing
was followed by 30 minute incubation at RT with the secondary Alexa
Fluor488 goat anti rabbit IgG (Invitrogen, Paisley, UK; 1:1000). Sections
were then rinsed and incubated with the primary anti-Ck19 Ab
(Eurogentec, Koln, Germany; 1:1000) for 1 h at RT, washed again, and
incubated with Alexa Fluor594 goat anti rabbit IgG (Invitrogen, Paisley,
UK; 1:1000) for 30 min at RT. After washing, the slides were covered
with vectashield+DAPI and visualized by confocal microscopy. Quanti-
ﬁcation of Ki67-positive cholangiocytes after 12 weeks of cholate diet
was perfomed in 5 animals per phenotype, 5 images per mouse. The re-
sults are expressed as a percentage of Ki67-positive in the total number
of cholangiocytes.
In BDL model, bromodeoxyuridine (BrdU) method was used for
counting proliferating cholangiocytes as previously described [27].Fig. 2. IGF1 overexpression promotes ﬁbrosis Abcb4−/− livers. (A) Sirius red staining of liver
of large bile duct strictures 12 weeks of cholate diet. (B) Percentage of ﬁbrotic area estimat
12 weeks of cholate diet. Y axis represents the ratio between collagen area and total tiss
Abcb4−/− and Abcb4−/− IGF1 mice. Asterisks denote signiﬁcance (Pb0.05).Shortly, formalin-ﬁxed and parafﬁn-embedded liver sections were
stained with mouse monoclonal anti-BrdU antibody (1:1000 GE
Healthcare, Barcelona, Spain), at 4 °C, overnight. Secondary
peroxidase-labeled goat anti-mouse antibody (Dako Envision System,
Carpinteria, CA)was incubated at room temperature for 30 min. Twoper-
sons unaware of the study groups scored BrdU positive cholangiocytes in
SMP8-IGF1 BDL (n=5) and WT BDL (n=5), analyzing 6 panels per
animal.
3. Results
3.1. Overexpression of IGF1 in Abcb4−/− mice
To study the long-term effect of IGF1 on the pathology of chron-
ic cholangiopathy, Abcb4−/− mice were crossbred with a transgenic
mouse expressing rat Igf1 behind an α-Sma promoter [17]. This restricts
rat Igf1 hepatic expression to the α-SMA expressing, activated hepatic
stellate cells (HSCs) [27]. To aggravate the pathology, after weaning the
animals were given a cholate-supplemented diet (0.03%) [15,18]. The
expression of rat Igf1 was conﬁrmed by qPCR in livers of the transgenic
(TG) Abcb4−/− IGF1 mice (Fig. 1A). Since rat Igf1 expression in TG miceof WT, Abcb4−/−mice and transgenic Abcb4−/− IGF1 mice with representative pictures
ed by image analysis of Sirius red stainings in Abcb4−/− and Abcb4−/− IGF1 mice after
ue area. (C) Hydroxyproline amount at 3, 6 and 12 weeks of cholate diet in livers of
Fig. 3. IGF1 overexpression hinders matrix remodeling in Abcb4−/− livers. (A–G) Relative mRNA level of Tgfβ1, Col1, 3, 4, tPA, Timp1, 2 and Tnfα in livers of WT, Abcb4−/− IGF1 and
Abcb4−/− mice after 3, 6 and 12 weeks of cholate diet. Asterisks denote signiﬁcant difference (Pb0.05).
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α-Sma expression, that remained comparable at all three time points
(Fig. 1B). IGF1 induces HGF expression in HSCs [28]. The signiﬁcant in-
crease of Hgf expression at 6 and 12 weeks in TG animals compared
with non-transgenic (NT) Abcb4−/− littermates conﬁrmed that IGF1
signaling was indeed enhanced (Fig. 1C).3.2. Overexpression of IGF1 induced liver ﬁbrosis in Abcb4−/− mice
Liver function tests were performed to investigate if IGF1 could pro-
tect this mouse model against the toxicity of bile salts, thereby reducing
chronic bile duct proliferation. Serum levels of ALT, AST, ALP and biliru-
bin signiﬁcantly increased in Abcb4−/− IGF1 and Abcb4−/− mice
compared with WT, indicating liver damage in both models (Table 1).
The initially high ALP serum levels, a result of osteoblast activity in
growing bones [29], decreased to normal after weaning (66–260 U/L).
After 12 weeks of cholate diet, however, ALP and bilirubin concentration
signiﬁcantly increased in the IGF1 transgenics compared with their
Abcb4−/− littermates, suggesting cholestasis and possibly an enhanced
progression of liver ﬁbrosis (Table 1).After 3 weeks of cholate diet, the fractional liver weight in Abcb4−/−
mice was signiﬁcantly higher than in Abcb4−/− IGF1 group. At 6 weeks
this difference had disappeared, while at 12 weeks there was even a
tendency toward an increased liver/body weight ratio in Abcb4−/−
IGF1mice (Fig. 1D). Sirius red staining andhydroxyprolinemeasurement
revealed a signiﬁcant increase in the amount of connective tissue in the
Abcb4−/− IGF1 group, indicating increased liver ﬁbrosis in transgenic
mice after 12 weeks of cholate diet (Fig. 2A–C). The increased expression
of the pro-ﬁbrotic transforming growth factor beta 1 (Tgfβ1), which stim-
ulates trans-differentiation of HSCs into myoﬁbroblasts and enhances
TIMP and collagen production [30], may also support the increased ﬁbro-
sis in IGF1 expression Abcb4−/− mice at 12 weeks (Fig. 3A). Also the
mRNA levels of Col1, 3 and 4 at 12 weeks were signiﬁcantly increased in
these mice (Fig. 3B–D), providing additional support that IGF1 enhanced
the progression of liver ﬁbrosis in the Abcb4−/−mouse model.
In addition to enhanced synthesis, the increased ECM deposition in
mice overexpressing IGF1 may also in part be due to reduced matrix
remodeling. Inhibition of matrix metalloproteinases (MMP) by their
tissue inhibitors (TIMPs) plays an important role in this process [31,32].
The signiﬁcantly increased expression of Timp1 and 2 after 12 weeks
suggested that tissue remodeling was reduced in the Abcb4−/− IGF1
Fig. 4. IGF1 overexpression induces expression of inﬂammatorymarkers in Abcb4−/−mice.
Relative mRNA level of Tnfα in livers of WT, Abcb4−/− IGF1 and Abcb4−/−mice after 3, 6
and 12 weeks of cholate diet. Asterisks denote signiﬁcant difference (Pb0.05). (B) The rep-
resentative pictures of F4/80 immunostaining in non-transgenic (left panel) and Abcb4−/−
IGF1 mice (right panel) after 12 weeks of cholate diet are shown. (C) Representative CK19
immunostaining of the same livers.
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creased expressionof tPa, an activator of plasminogen that plays an essen-
tial role in the activation of MMP needed for tissue remodeling [33].
3.3. Overexpression of IGF1 enhances inﬂammation in Abcb4−/− liver
Inﬂammation due to regurgitation of bile acids plays an important role
in the development of pathology in the Abcb4−/− mice. The increased
pathology in Abcb4−/− IGF1 animals was accompanied by an increased
inﬂammation, as shown by the enhanced expression of Tnfa (Fig. 4A).
Immunostaining for F4/80, a marker for inﬁltrating macrophages and
liver-resident Kupffer cells, was higher at 12 weeks in Abcb4−/− IGF1
animals, which suggested an increased inﬂux of macrophages compared
with non-transgenic controls (Fig. 4B).
3.4. Overexpression of IGF1 increases cholangiocyte proliferation in
Abcb4−/− mice
Since bile duct proliferation is one of the major characteristics of the
pathology in Abcb4−/− mice, and cholangiocytes are target of IGF1
signaling [12], the increased pathology could be due to an enhanced
cholangiocyte proliferation in response to the IGF1 overexpression.
Therefore, the level of, the cholangiocyte marker Ck19 was determined
in these livers. A signiﬁcant increase in mRNA expression level and an
increased presence of Ck19-expressing cells detected by immunohisto-
chemistry conﬁrmed an enhanced presence of cholangiocytes in the
transgenic animals (Figs. 5C and 4C). Subsequently, the expression of
the proliferationmarker Ki67was determined to investigate if this effect
was caused by a higher proliferation. Although a higher Ki67 level was
observed, the difference did not reach signiﬁcance (Fig. 5B). This lack ofsigniﬁcance could be due to the fact that the proliferationwas not limited
to cholangiocytes, hence the proliferation of biliary epithelium was
determined by ﬂuorescent cell labeling and co-localization for Ck19
and Ki67. This indicated an ongoing proliferation of Ck19 positive cells
in the transgenic animals (Fig. 5A). Quantiﬁcation of Ki67-positive
cholangiocytes with respect to the total number of cholangiocytes
demonstrated a signiﬁcant increase in bile duct proliferation in IGF1
overexpressing animals after 12 weeks of cholate diet (Fig. 5D). This
enhanced proliferation of biliary epithelium could have resulted in the
formation of numerous large bile duct structures seen in the IGF1
overexpressing mice (Fig. 2A).
3.5. Overexpression of IGF1 in BDL model
Though Abcb4−/− is a relevant model for chronic cholangiopathy, it
does not reproduce all features of acute models of cholestasis, e.g. CCl4-
and BDL-induced. To compare the effect of IGF1 in Abcb4−/− mice with
that in an acute model, we used BDL to induce acute cholestasis in
SMP8-IGF1 mice. Sirius red staining of livers in BDL-treated SMP8-IGF1
and WT animals demonstrated ﬁbrosis in peribiliary areas (data not
shown). Upon BDL, the expression of IGF1 was signiﬁcantly higher in
transgenic SMP8-IGF1 mice in comparison with sham-operated animals
indicating transgenic upregulation by cholestatic injury. Changes in
gene expression proﬁles in BDL treated animals and liver function test
(ALT, AST, ALP and bilirubin) conﬁrmed the development of liver ﬁbrosis
in both SMP8-IGF1 andWTmice (Table 2). The number of a-Sma express-
ing activated HSCs increased, and was accompanied by an increased scar
formation reﬂected by higher Col1 levels, by increased cholangiocyte pro-
liferation demonstrated by higher Ck19 levels, and more inﬂammation
based on Tnfα expression.
The gene expression data one week after BDL did not reveal an
increased development of ﬁbrosis in SMP8-IGF1 mice compared to WT
mice. In fact, the only signiﬁcant difference was a decreased expression
of α-Sma in transgenic compared to WT (Table 2), while that of Tnfα,
Tgfβ, and Col1 did not differ between the models. In contrast to the
Abcb4−/− model, IGF1 overexpression did not cause an increased
Ck19 level in BDL-treated mice (Table 2). This absence of an effect on
proliferation was conﬁrmed by the similar percentage of BrdU-positive
cholangiocytes (Table 2). In conclusion, in contrast to the chronic
model for bile duct damage, increased IGF expression did not affect
pathology in the acute BDL model, but did not display a protective effect
either.
4. Discussion
Prolonged overexpression of IGF1 increased ﬁbrosis in the Abcb4−/−
mouse, a model for primary sclerosing cholangitis. The enhanced IGF1
signaling resulted in stimulated cholangiocyte proliferation, one of the
main pathological features of the liver damage in these mice.
The expression of transgenic Igf1, controlled by the α-Sma promoter,
was stable during the entire experiment. It was previously reported that
in Abcb4−/− mice expression of α-Sma (also of pro-ﬁbrotic Tgfβ and
Pdgfr) reachesmaximum at 4 weeks of age and then gradually decreases
[34]. This was due to the generation of ﬁbrous septa that shield the
healthy liver from the toxic bile, thereby limiting the increase in pro-
ﬁbrotic factors. In our study, the expression of pro-ﬁbrotic factors in
the Abcb4−/− mice remained high, resulting in a hydroxyproline level
about 2-fold higher than previously reported. The difference between
the studies is most likely due to the cholate diet, which enhances the
pathology in this model, resulting in prolonged high expression of
pro-ﬁbrotic factors [15].
IGF1 induces the expression of hepato-protective HGF in HSCs [28].
Conﬁrming our previous observation [27], Hgf mRNA levels also
increased in the IGF1 overexpressing Abcb4−/− mice compared to
the non-transgenic litter-mates. The extent of damage in this
model is much less severe than in the previously used acute CCl4
Fig. 5. IGF1 overexpression in Abcb4−/−mice enhances proliferation of cholangiocytes: (A) Representative pictures of double staining for Ck19, Ki67 in Abcb4−/− (left panels) and
Abcb4−/− IGF1 (right panels) after 12 weeks of cholate diet. (B–C) Relative gene expression of Ki67 and Ck19 in control, Abcb4−/− and Abcb4−/− IGF1 mice. (D) Percent of
Ki67-positive cholangiocytes with respect to the total number of cholangiocytes, as detected by immunohistochemistry.
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increase of AST and ALT in serum of the Abcb4−/−mice was compa-
rable with the data reported before for this model [15], and indicat-
ed an ongoing liver damage. The elevation of serum ALP and
bilirubin after 12 weeks of cholate diet points to an increase in pro-
gression of bile duct damage in mice that overexpress IGF1. This
worsening of pathology was subsequently conﬁrmed by the in-
creased level of hydroxyproline and collagen, indicating an en-
hanced deposition of ECM. Thus, in contrast to our previous study
in animals with CCl4- induced parenchymal damage, in the present
work IGF1 overexpression enhanced the damage and increased por-
tal ﬁbrosis in the cholangiopathic livers of Abcb4−/− mice. The dis-
crepancy between the previous where severe hepatocyte damage
occurs, and the current study where bile-duct proliferation is one
of the most prominent symptoms indicative of severe damage to
the bile duct, is in part caused by the different models used. The
IGF1 produced by hepatocytes is bound to IGFBP3, also produced
by these cells, and efﬁciently secreted into the circulation. Therefore
the IGF1 expressed by hepatocytes upon viral delivery, just like IGF1
injected, will be mainly present in the circulation, affecting many
organs including the intestine. IGF1 produced by activated stellate
cells that also produce collagen deposits will likely bind to the ECM
and not reach the systemic circulation. It could instead act as an autocrine
factor. In this respect, the increased production of IGFBP5 by HSCs may
also be relevant, since IGF1-IGFBP5 complex has a high afﬁnity for the
ECM.Fibrogenesis depends on tissue remodeling, composed of strictly
controlled processes. A subtle balance of MMPs (mainly involved in
the ECM degradation) and TIMPs (their endogenous inhibitors)
modulates liver ﬁbrogenesis [35]. MMPs are regulated by uPA/tPA/
plasmin proteases, which directly contribute to the degradation of
collagens, and so play a pivotal role in the maintenance of ECM and
tissue homeostasis [36–38]. IGF1 overexpression increased the
expression of Timp1, which could reduce MMP activity and ECM
degradation in Abcb4−/− IGF1 animals. Moreover, lower tPA ex-
pression points to a less active tissue remodeling resulting in a
more prominent ﬁbrosis in IGF1 overexpressing mice, which may
further promote liver ﬁbrosis.
Several studies have shown that bile-duct epithelium cells, in con-
trast to hepatocytes, express the IGF1R and directly respond to IGF1.
IGF1 enhances proliferation and survival of cholangiocytes via IRS1/2
and ERK and PI3-kinase pathways [12]. The proliferative effect of IGF1
has also been reported for smooth muscle cells in IGF1-overexpressing
mice [17]. Activation of the IGF1 system improves the survival of
cholangiocytes in PBC patients suffering from chronic bile duct damage
[39]. In the acute CCl4 model, IGF1 did not reduce the initial damage,
but caused a more rapid DNA synthesis, resulting in liver regeneration
[27]. Depletion of IGF1R reduces ductular and ﬁbrogenic responses and
increased cholestasis tolerance in BDL mice [40]. The damage in the
Abcb4−/− mouse is chronic, less severe, and localized to the portal
areas [16]. This results in a persistent increase in IGF1 signaling in the
portal area, enhancing cholangiocyte proliferation [12]. Biliary epithelial
Table 2
Plasma liver function parameters, hepatic mRNA expression levels, and percentage of BrdU-positive cholangiocyte in WT and SMP8-IGF1 mice in response to BDL.
Liver function tests WT ctrl WT BDL SMP8-IGF1 ctrl SMP8-IGF1 BDL
AST 133.30±59.90 730.70±186 *0.03 113.30±47.72 507.20±158.70*0.04
ALT 77±48.08 777±262*0.03 #0.04 73.67±38.84 386.20±105.40*0.02
ALP 83±10.17 1543±332.90*0.03 112.30±14.47 1333±523.60*0.02
Bilirubin 0.08±0.01 10.07±0.65*6E−05 0.10±0.02 11.23±2.09*5E−12
mRNA expression
transgen Igf1 No expression No expression 2.28±0.63 5.03±2.13*0.02
αSma 1.56±0.69 23.55±7.69*0.0002 #0.02 2.53±0.33 11.65±5.44*0.006
Ck19 1.22±0.54 7.04±3.09*0.003 1.47±0.83 10.63±4.70*0.003
Tnfα 6.83±3.63 214.35±88.56*0.0008 9.22±7.08 115.68±56.46*0.003
Col1 0.73±0.82 1.18±0.79 0.31±0.19 0.78±0.17*0.004
Tgfβ 1.34±0.89 1.73±1.07 1.35±0.01 1.34±0.61
Asbt 19.16±13.64 25.01±15.68 20.89±4.72 49.07±20.57*0.01
BrdU+ cholangiocytes (%) 11.69±4.30 12.70±5.89
The table shows mean values and standard deviations of liver function parameters and hepatic mRNA expression levels (relative to housekeeping 36B4) in WT and SMP8-IGF1 mice
and one week after BDL treatment and in sham-operated controls (n=5 per group). Percentage of BrdU-positive cholangiocytes was assessed in WT and SMP8-IGF1 mice 1 week
after BDL. Asterisks denote signiﬁcant difference between sham-operated animals and BDL counterparts; hashtags indicate signiﬁcant difference between BDL groups (with the
corresponding P-values shown next to the tags).
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deposition that was observed in our IGF1-overexpressing mice. In BDL
induced ﬁbrosis, Ck19 is co-localized with type 1 and 3 collagen [41],
pointing to the capacity of these cell to produce collagen. Furthermore,
BECs in chronic cholangiopathies participate in ﬁbrogenesis by undergo-
ing epithelial–mesenchymal transitions EMT [42]. They lose their epithe-
lial distinctiveness and acquire a mesenchymal phenotype and ability to
migrate and produce ECM components, like collagen [43]. It is known
that cholangiocytes treated with HGF have an attenuated transition
toward a mesenchymal phenotype [41], hence the increased Hgf and
CK-19 gene expression level in IGF1-overexpressing Abcb4−/−mice sug-
gests a decreased transition. Our data, with relatively large fold-changes
in BECs-speciﬁc, and small changes in HSCs-speciﬁc genes, could there-
fore indicate that the effect that IGF1 exerts on BECs cells is stronger
than that on HSCs. In response, BECs cells have high proliferation and
are likely responsible for production of components of extracellular
matrix.
In addition, IGF1 enhances the proliferation of liver cystic epithelium
and reduction of its expression reduces the size of liver cysts in a mouse
model [44]. A similar action may explain the formation of extremely
large, but ill-developed bile-duct structures observed in thosemice, lead-
ing to the formation of strictures. Presence of structures may explain the
cholestasis that, according to serum bilirubin and ALP level, developed
eventually in our transgenic mice. Alternatively, the increased prolifera-
tion of bile ducts could promote the cholehepatic shunt [45], thereby
increasing the amount of bile salts reaching the hepatocytes.
Submitting SMP8-IGF1 and WT mice to BDL revealed an absence of
protective effect of overexpression of IGF1 also in this model. However,
no difference in bile duct proliferation was seen between the WT and
the SMP8-IGF1 mice. BDL did induce a-Sma mRNA expression in both
models, suggesting that 1 week was enough to enhance IGF1 signaling.
Nevertheless, 1 week BDL protocol seemed insufﬁcient to induce the
extent of liver damage needed to reveal an effect of enhanced IGF1
signaling.
Bile duct proliferation increased in IGF1 overexpressing Abcb4−/−
and showed a tendency to increase in the SMP8-IGF1 mice submitted
to BDL based on Ck-19 expression and BrdU staining. Increased Asbt
expression in SMP8-IGF1 BDL mice suggests an increased cholehepatic
shunt of bile salts, probably in an attempt to reduce the presence of
damaging bile salts in biliary ducts. Likewise, Abcb4−/− mice showed
an increased expression of Asbt [45]. The augmented expression of IGF1
in Abcb4−/− IGF1 mice could result in an even higher increase of Asbt
that would enhance the excessive return of bile salts to the hepatocyte.
Thus although these responses are aimed at the protection and repair of
the bile duct epithelium, the additional increase of IGF1 to supra-normal
levels induced extensive proliferation resulting in more bile duct
abnormalities.A difference in pathogenesis between the models may explain the
discrepancy of the effect of IGF1 seen between Abcb4−/− mice and
othermousemodels of liverﬁbrosis (e.g. BDL- andCCl4-induced). Ligation
of the common bile duct results in an acute interstitial (biliary) ﬁbrosis,
associated with massive proliferation of bile ducts that is only rarely ob-
served in man. On the other hand, progression of ﬁbrosis in Abcb4−/−
mice is spontaneous due to cholangiocyte proliferation and massive
up-regulation of proﬁbrogenic genes, and bears more resemblance to
human biliary ﬁbrosis [34]. In addition, IGF1 overexpressed by hepato-
cytes upon viral delivery (just like injected IGF1) would be present in
circulation and exert a systemic effect. In contrast, IGF1 produced by acti-
vated HSCs would likely bind to the ECM (also formed by these cells)
without reaching the systemic circulation. It could instead act as an auto-
crine factor. In this respect, the increased production of IGFBP5 by HSCs
[46] may be relevant, since complex IGF1-IGFBP5 has a high afﬁnity for
the ECM.
Our data demonstrate that a rise in IGF1 expression in Abcb4−/−
mouse, model for primary sclerosing cholangitis, worsens the pathology
by increasing cholangiocyte proliferation leading to the formation of bile
duct strictures, comparable with those in patients [47]. This indicates
that, in contrast to chronic parenchymal live damage, IGF1 administra-
tion does not seem an option for treating ﬁbrosis caused by chronic
cholangiopathies, and should be taken into account in the design of
IGF1 replacement therapy for cirrhotic patients.
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